Clinical Trial

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Name: Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS — clinical trial record (NCT05379985)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

Protocol Amendment History 11 amendments

This ClinicalTrials.gov record has been amended 11 times since 2022-05-13; most recent amendment 2026-05-12.

Status change: Not Yet Recruiting → Recruiting 2022-06-28

Trial Details

NCT Number	NCT05379985
Lead Sponsor	Revolution Medicines, Inc.
Conditions	Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Enrollment	754 participants
Start Date	2022-05-31
Primary Completion	2027-05-31 (estimated)
Study Completion	2027-07-26 (estimated)
Updated on ClinicalTrials.gov	2026-05-15